Immunocore (IMCR) News
NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
26.41-0.22 (-0.83%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMCR news summary
We found 7 recent headlines mentioning Immunocore (IMCR): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, IMCR is down 0.83% at $26.41. The most recent story, "Immunocore to present at upcoming investor conferences", was published by GlobeNewswire on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Immunocore headlines
- Immunocore to present at upcoming investor conferences(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company…GlobeNewswire
- Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanomaIn 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients…GlobeNewswire
- Immunocore reports third quarter financial results and provides a business updateKIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to dateGlobeNewswire
- Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingImmunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingGlobeNewswire
- EU Approves Expanded Use of ABBV's Tepkinly in Follicular LymphomaAbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.NasdaqABBV, AMRN, GMAB, IMCR
- FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer TherapyImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.NasdaqIMCR, IBRX, INDV
- ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder CancerIBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.NasdaqIMCR, IBRX, INDV